▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Mark Prvulovic

XMFmarkprvulovic

Before joining The Motley Fool, Mark worked as a freelance financial writer covering a variety of markets. Now he spends most of his time researching promising biotech and cannabis stocks, but from time to time will write about whatever catches his interest no matter the industry.

Recent Articles by Mark Prvulovic

COVID vaccine dollars bills

Aug 12, 2020 by Mark Prvulovic

Is Vaxart Stock a Buy?

This hot little coronavirus stock is up over 2,500%. Could it rise even more?

chalk board stock market

Aug 12, 2020 by Mark Prvulovic

2 Promising Growth Stocks That Everyone's Forgetting About

Investors shouldn't forget about these two high-growth companies.

COVID-19 test tubes

Aug 11, 2020 by Mark Prvulovic

Is It Too Late to Buy Inovio Stock?

Have on-the-fence investors missed the train on this hot coronavirus stock?

stethoscope money 2

Aug 10, 2020 by Mark Prvulovic

Is Exelixis a Buy?

This obscure biotech stock could be an excellent long-term investment.

marijuana plant cash

Aug 7, 2020 by Mark Prvulovic

3 Reasons I'm Cautious About Canopy Growth Stock

Not all is rosy for this cannabis giant. Here are a few things you should keep in mind about Canopy.

COVID-19 vaccine vial

Aug 6, 2020 by Mark Prvulovic

Is Now the Right Time to Buy Novavax Stock?

Following strong clinical data from its COVID-19 vaccine, shares of Novavax are trading at record highs.

GettyImages-968289652

Aug 5, 2020 by Mark Prvulovic

Is Aimmune Therapeutics a Buy?

Is this battered biotech stock now a good deal for investors?

rising stock arrow pharma

Aug 5, 2020 by Mark Prvulovic

3 Pharmaceutical Stocks That Can Make You Rich

Some of the most promising stocks on the market right now are pharmaceuticals.

stock arrow downwards 2

Aug 3, 2020 by Mark Prvulovic

What Should Investors Think of Aphria's Unexpected Quarterly Loss?

This once-profitable cannabis company reported a $99 million net loss. Is this a bad sign of things to come?

coronavirus 7

Aug 3, 2020 by Mark Prvulovic

Is BioCryst Pharmaceuticals Stock a Buy?

Forget its coronavirus treatment, berotralstat could be BioCryst's next blockbuster drug.

cannabis oil 1

Aug 1, 2020 by Mark Prvulovic

Should Investors Buy GW Pharma Stock Right Now?

Wall Street analysts think this stock could double. Are they right?

COVID-19 vial stock market

Jul 30, 2020 by Mark Prvulovic

The 1 Promising Coronavirus Stock No One Knows About Yet

Kamada might be the least well-known biotech company working on a COVID-19 treatment right now.

2020 coins savings

Jul 28, 2020 by Mark Prvulovic

3 Safe and Cheap Dividend Stocks to Buy

You'll be surprised at just how much some of these companies pay out in dividends.

GettyImages-1060858272

Jul 27, 2020 by Mark Prvulovic

5 Winning Stocks That Will Continue to Thrive in 2020

From gold miners to vaccine developers, these companies have been killing it so far this year.

stethoscope market up

Jul 24, 2020 by Mark Prvulovic

Could This Obscure Biotech Stock Make You a Fortune?

Two major catalysts on the horizon could send Omeros' stock soaring. What should investors think?

marijuana plant

Jul 24, 2020 by Mark Prvulovic

3 Pot Stocks That Could Become Big Winners in 2020

These cannabis companies have a lot of good things going for them right now. Here's why.

vet and dog

Jul 17, 2020 by Mark Prvulovic

Is Elanco Stock a Buy?

Despite mediocre financial results, could a major upcoming acquisition be what this company needs to succeed?

stock chart rising up 2

Jun 11, 2020 by Mark Prvulovic

This Biotech Stock Doubled Last Month. Is it a Buy?

CAR-T drugs are all the rage right now, but is this stock worth the hype?

GettyImages-1090501692

Jun 4, 2020 by Mark Prvulovic

Is Canopy Growth at Risk of Going Bankrupt?

Should investors be worried about this pot industry giant going out of business?

person money growing

Jun 2, 2020 by Mark Prvulovic

Could This Obscure Biotech Stock Make Early Investors a Fortune?

If you haven't heard of Akero Therapeutics before, take note. Its NASH drug candidate could be a game changer.

HOW THE MOTLEY FOOL CAN HELP YOU

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services